JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business

At the start of 2020's J.P. Morgan Healthcare Conference, news of a strange, pneumonia-like disease outbreak in China was only days old, and Moderna and BioNTech were unproven biotechs thought to be years away from having marketed products.

Fast forward to 2021 and those companies have, in record time, each developed highly effective coronavirus vaccines that hold the promise to curb what's become the world's worst pandemic in a century.